Immunic, Inc. (IMUX)
Oxford Ledge is still expanding full research coverage of IMUX. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
Immunic develops oral small-molecule therapies for multiple sclerosis and gastrointestinal diseases through three programs at various development stages.
SEC filings
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-07-14
- 8-K Departure/election of directors or officers 2026-07-06
- 8-K Departure/election of directors or officers; Shareholder vote results; Financial statements and exhibits 2026-06-29
- DEF 14A Proxy statement for shareholder vote 2026-05-29
- 8-K Regulation FD disclosure; Financial statements and exhibits 2026-05-28
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for IMUX. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open IMUX in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.